A recent clinical trial reported that in patients with previously untreated ER-positive, HER2-negative advanced breast cancer, the combination of palbociclib with letrozole produced a longer progression-free survival than letrozole alone (Finn et al., 2016). Here, ESR1 is linked to breast carcinoma.